Ameriprise
KRYS icon

Ameriprise’s Krystal Biotech KRYS Stock Holding History

Ameriprise’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.9M Sell
49,837
-2,508
-5% -$667K ﹤0.01% 1734
2025
Q4 		$12.9M Sell
52,345
-3,447
-6% -$726K ﹤0.01% 1718
2025
Q3 		$9.85M Sell
55,792
-7,043
-11% -$1.05M ﹤0.01% 1920
2025
Q2 		$8.64M Buy
62,835
+2,327
+4% +$342K ﹤0.01% 1924
2025
Q1 		$10.9M Sell
60,508
-52,968
-47% -$8.91M ﹤0.01% 1699
2024
Q4 		$17.8M Buy
113,476
+23,727
+26% +$4.21M ﹤0.01% 1403
2024
Q3 		$16.3M Sell
89,749
-12,247
-12% -$2.36M ﹤0.01% 1446
2024
Q2 		$18.7M Buy
101,996
+58,605
+135% +$9.84M 0.01% 1325
2024
Q1 		$7.72M Buy
43,391
+27,452
+172% +$3.81M ﹤0.01% 2020
2023
Q4 		$1.98M Buy
15,939
+3,960
+33% +$439K ﹤0.01% 2880
2023
Q3 		$1.39M Buy
+11,979
New +$1.46M ﹤0.01% 2998
2020
Q3 		– Sell
-28,806
Closed -$1.19M – 3760
2020
Q2 		$1.19M Buy
28,806
+12,996
+82% +$625K ﹤0.01% 2851
2020
Q1 		$684K Buy
+15,810
New +$827K ﹤0.01% 2986

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ameriprise's KRYS Position: Q1 2026 in Review

Ameriprise reduced its Krystal Biotech (KRYS) stake by 4.8% in Q1 2026, selling an estimated $667K and leaving 49,837 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1734.

Ameriprise first reported a position in KRYS in Q1 2020 and has held it in 13 quarters since. The position peaked at $18.7M in Q2 2024. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Ameriprise held 49,837 shares of Krystal Biotech worth $12.9M as of Q1 2026.
  • Ameriprise sold 2,508 Krystal Biotech shares in Q1 2026, an estimated $667K.
  • Krystal Biotech made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #1734 holding.
  • Ameriprise first reported a position in Krystal Biotech in Q1 2020 and has held it in 13 quarters since.
  • Ameriprise's Krystal Biotech position peaked at $18.7M in Q2 2024.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.